Marsico Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Marsico Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-416,292	Closed	-$67.8M	–	87
2018 Q1	$67.8M	Buy	+416,292	New	+$68M	2.55%	13
2015 Q4	–	Sell	-1,869,291	Closed	-$195M	–	97
2015 Q3	$195M	Sell	1,869,291 -81,272	-4%	-$10.4M	2.03%	20
2015 Q2	$241M	Sell	1,950,563 -209,553	-10%	-$26.4M	2.13%	18
2015 Q1	$255M	Buy	+2,160,116	New	+$259M	2.15%	19

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Marsico Capital Management's VRTX Position: Q2 2018 in Review

Marsico Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 416,292 shares — an estimated $67.8M sold.

Marsico Capital Management first reported a position in VRTX in Q1 2015 and held it in 4 quarters. The position peaked at $255M in Q1 2015. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Marsico Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Marsico Capital Management sold 416,292 Vertex Pharmaceuticals shares in Q2 2018, an estimated $67.8M.
Marsico Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 4 quarters.
Marsico Capital Management's Vertex Pharmaceuticals position peaked at $255M in Q1 2015.
689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Marsico Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.